Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Evaluating adverse events related to 177Lu-PSMA-617 in PSMA-positive mHSPC

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the side effects associated with 177Lu-PSMA-617 treatment, which was assessed in the PSMAddition trial (NCT04720157). In patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), fatigue was more common in the lutetium-treated group, and other adverse events, such as dry mouth, were related to the sites of target expression, including the salivary and lacrimal glands, and the small intestine. Gastrointestinal toxicity, including nausea, vomiting, and changes in appetite and bowel movements, were also more common in the lutetium-treated group. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So there’s often constitutional side effects or adverse events in the way of fatigue. And there was more fatigue in the lutetium-treated group. Most of the other ones, at least, are associated with sites of the target expression. So the salivary and lacrimal glands, the small intestine. Well, those really. So dry mouth was the most common, 46%. Diarrhea didn’t make the top 10%, but it was more common than the control...

So there’s often constitutional side effects or adverse events in the way of fatigue. And there was more fatigue in the lutetium-treated group. Most of the other ones, at least, are associated with sites of the target expression. So the salivary and lacrimal glands, the small intestine. Well, those really. So dry mouth was the most common, 46%. Diarrhea didn’t make the top 10%, but it was more common than the control. And GI toxicity. So whether we’re talking about nausea, vomiting, appetite, bowel movement changes, those were all more common in the lutetium-treated group. We think because of the target.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...